Welcome to our dedicated page for Journey Medical Corporation news (Ticker: DERM), a resource for investors and traders seeking the latest updates and insights on Journey Medical Corporation stock.
Journey Medical Corporation (symbol: DERM) is a commercial stage pharmaceutical company dedicated to the development and commercialization of products designed to treat dermatological conditions. With a diverse portfolio that includes eight branded and three authorized generic prescription drugs marketed in the United States, Journey Medical is committed to improving the quality of life for patients with skin conditions.
Among the well-known products in their lineup are Qbrexza, a topical treatment for excessive underarm sweating, Accutane, a potent medication for severe acne, Amzeeq, a foam treatment for acne vulgaris, and Exelderm, an antifungal solution. These products highlight the company's dedication to addressing various dermatological needs.
Recently, Journey Medical secured additional capital to support general corporate purposes, including funding for the potential launch of DFD-29. This demonstrates their strategic effort to expand their product offerings and enhance their market presence.
The company is proactive in maintaining transparent communication with its stakeholders. They have scheduled a conference call on March 21, 2024, to discuss financial results and provide a corporate update. Furthermore, another conference call is set for May 13, 2024.
Looking ahead, an important milestone for Journey Medical is the Prescription Drug User Fee Act (PDUFA) goal date on November 4, 2024. This date is crucial for the approval process of their new drug applications, reflecting the company's ongoing efforts in drug development and commercialization.
For more information, investors and interested parties can contact Jaclyn Jaffe at (781) 652-4500 or via email at ir@jmcderm.com. Media inquiries can be directed to Tony Plohoros at (908) 591-2839 or tplohoros@6degreespr.com.
Journey Medical Corporation (Nasdaq: DERM) announced that Ernest De Paolantonio will step down as Chief Financial Officer effective January 27, 2023, to pursue another opportunity. Joseph M. Benesch has been appointed as Interim Chief Financial Officer from the same date. Claude Maraoui, CEO, noted Benesch's extensive experience and preparation for this leadership role. An internal and external search for a permanent CFO is underway. De Paolantonio will consult until March 31, 2023, ensuring a smooth transition. This change comes as Journey Medical anticipates significant milestones, including topline data from Phase 3 clinical trials in the first half of 2023.
Journey Medical Corporation (NASDAQ: DERM) has completed enrollment for its Phase 3 clinical trials assessing the safety and efficacy of DFD-29 for the treatment of papulopustular rosacea. The trials will compare DFD-29 with current treatments and aim to file a New Drug Application in late 2023. Preliminary Phase 2 trial results indicated DFD-29 is nearly twice as effective as doxycycline. The combined trials target 640 adult patients, and the company anticipates peak annual sales could exceed $100 million upon approval.
Journey Medical Corporation (NASDAQ: DERM) announced positive pharmacokinetic (PK) comparability data for its drug DFD-29 in a Phase 3 study focused on treatment for papulopustular rosacea. Conducted in collaboration with Dr. Reddy’s Laboratories, the study showed DFD-29's systemic exposure was significantly lower than SOLODYN, with no food effect on its pharmacokinetics. With enrollment at 96%, Journey Medical anticipates topline data in the first half of 2023 and plans to file a New Drug Application later in the year, aiming to provide an effective treatment for millions suffering from rosacea.
Journey Medical Corporation (Nasdaq: DERM) announced its management team will present at the Cantor Medical & Aesthetic Dermatology Conference on December 8, 2022, in Miami, FL. CEO Claude Maraoui will participate in a panel titled, “Is Derm Defensive?: Commercial Successes, Current & Upcoming Launches,” at 9:00 a.m. ET. Journey Medical focuses on dermatological products and currently markets eight treatments for skin conditions. The Company was founded by Fortress Biotech (Nasdaq: FBIO) and files periodic reports with the SEC.
Journey Medical reported a 26% revenue increase to $57.7 million for the first nine months of 2022, despite third-quarter sales declining to $16.1 million, affected by Targadox generic competition. The company has achieved 75% enrollment in its DFD-29 Phase 3 trials for treating papulopustular rosacea, with top-line data expected in H1 2023. Journey Medical anticipates submitting a New Drug Application in H2 2023, predicting DFD-29 could generate over $100 million in peak annual sales. Cash reserves totaled $34.9 million as of September 30, 2022.
Journey Medical Corporation (Nasdaq: DERM) announced it will release its third quarter 2022 financial results on November 10, 2022, after market close. A conference call to discuss these results will take place at 4:30 p.m. ET the same day. Interested parties can participate by calling specific numbers provided in the announcement. Journey Medical, based in Scottsdale, Arizona, develops and commercializes innovative dermatological products, having successfully marketed eight treatment products to date.
Journey Medical Corporation (Nasdaq: DERM) announced CEO Claude Maraoui's participation in two upcoming investor conferences. The first is the Roth Inaugural Healthcare Opportunities Conference on October 6, 2022, at 12:15 p.m. ET in New York City, which includes one-on-one meetings. The second is the LD Micro Main Event XV Conference on October 25, 2022, at 3:00 p.m. PT in Los Angeles, also with one-on-one meetings. Journey Medical focuses on dermatological products and markets nine branded and three authorized generic products.
Journey Medical Corporation (NASDAQ: DERM) has enrolled over 50% of participants in its Phase 3 trials evaluating DFD-29 (Minocycline Modified Release Capsules 40 mg) for treating papulopustular rosacea. This milestone indicates progress in collaboration with Dr. Reddy’s Laboratories. The company anticipates topline data in early 2023, followed by a New Drug Application filing later that year, expecting DFD-29 to achieve peak annual sales exceeding $100 million. Previous Phase 2 trials showed DFD-29's efficacy nearly double that of doxycycline in reducing inflammatory lesions.
Journey Medical reported a 20% increase in net revenue for Q2 2022, totaling $18.3 million, compared to $15.3 million in Q2 2021. This growth was supported by settlement agreements with Padagis ensuring exclusivity for key products. Enrollment in the DFD-29 Phase 3 trials is progressing, with top-line data expected in early 2023 and an NDA filing anticipated in the second half of 2023. Despite a $7.5 million net loss, there was an improved Non-GAAP Adjusted EBITDA loss of $(2.6) million. The company’s cash reserves are at $38.1 million.
Journey Medical Corporation (NASDAQ: DERM) will release its Q2 2022 financial results on August 9, 2022, after market close. A conference call will follow at 4:30 p.m. ET, allowing investors to discuss the results and receive a corporate update. Interested participants can dial in 10 minutes early and join the call. A live audio webcast will also be available on their website, with a replay option for 30 days. Journey Medical focuses on developing and commercializing dermatology products, with nine marketed treatments currently.
FAQ
What is the current stock price of Journey Medical Corporation (DERM)?
What is the market cap of Journey Medical Corporation (DERM)?
What does Journey Medical Corporation do?
What are some of Journey Medical's key products?
What recent achievements has Journey Medical Corporation made?
When is the next conference call for Journey Medical?
What is the PDUFA goal date for Journey Medical?
How can I contact Journey Medical for investor relations?
Who handles media relations for Journey Medical?
What is DFD-29?
Where are Journey Medical's products marketed?
What is the focus of Journey Medical Corporation?
